ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR - News) today provided a progress update on its large, formal pharmacokinetic (PK) study of its investigational drug Zenvia (dextromethorphan/quinidine [DM/Q]). Findings from the formal PK study will be used to support identification of an alternative formulation of Zenvia for diabetic peripheral neuropathic (DPN) pain. The alternative dose formulation is intended to deliver similar efficacy as observed in the first Phase III clinical study in DPN pain but with an improved safety and tolerability profile. The Company has completed the first three dosage cohorts in the formal PK study and has initiated the last two dosage cohorts. Data from the first three dosage cohorts indicate that there were no serious adverse events (SAEs) reported and only 1 of 48 subjects discontinued the study.
